Article Sidebar

PDF
Date Published: 10/02/2023
Abstract Views: 266
Views PDF: 138
DOI: https://doi.org/10.51298/vmj.v520i1B.3857
Issue
Vol. 520 No. 1B (2022)
Section
Các bài báo
How to Cite
Nguyễn , T. M. H., & Vũ , H. T. (2023). SURVIVAL STUDY AND SOME FACTORS AFFECTING IN OLD PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED BY THE FIRST MOLECULAR TARGETED AGENT. Vietnam Medical Journal, 520(1B). https://doi.org/10.51298/vmj.v520i1B.3857

SURVIVAL STUDY AND SOME FACTORS AFFECTING IN OLD PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED BY THE FIRST MOLECULAR TARGETED AGENT

Thị Minh Hải Nguyễn 1,, Hồng Thăng Vũ 2
1 19-8 Hospital, Ministry of Public Security
2 Hanoi Medical University

Main Article Content

Abstract

Objectives:  To study the survival and some factors influencing on the survival in old patients with advanced non small cell lung cancer treated by the fisrt molecular targeted agent. Patients and method: A retrospective study. The patient diagnosed adenocarcinoma non small cell lung cancer stage IV, age > 60 years, EGFR mutations (exon 19 deletion mutation or L858R) at Vietnam National Cancer Hospital, from March 2017 to March 2022 treat with the first molecular targeted agent. Results: 97 patients with the overall response rate were 66%, disease control rate were 85.6%.  Median progression free survival was 11.6 ± 4.8 months, median overall survival was 25.7 ± 4.9 months. Brain metastasis significantly related the overall survival. Conclusion: Gefitinib or Erlotinib prolonging survival in old patients with advanced non-small cell lung cancer EGFR mutations positive.

Article Details

Keywords

non small cell lung cancer, elderly patinets, tyrosine kinase inhibitor, Gefitinib, Erlotinib

References

1. GLOBOCAN. International agency for research on cancer. 2018.
2. Nguyễn Bá Đức (2004), “Ung thư phổi”, Hóa chất điều trị bệnh ung thư. NXB Y học Hà Nội, 64-74.
3. Nguyễn Bá Đức, Bùi Công Cường, Trần Văn Thuấn (2008), “Ung thư phổi”, Chẩn đoán và điều trị bệnh ung thư. NXB Y học, 176-188.
4. Harvey I. Pass, David P. Carbone, John D. Mina: “Lung Cancer”. Principles and practice, thirs edition 2005.
5. Socinski MA, Evans T, Gettinger S, et al (2013), Treatment of stage IV non small cell lung cancer: Diagnosis and management of lung cancer, 3 rd: American College of Chest Physicians evidence-based clinical practice guidelines, Chest; 143: 341s-368s.
6. Minami S, Kijima T (2015). Pemetrexed in maintenance treatment of advanced non squamous non-small- cell lung cancer. Lung cancer, 6, 13-25.
7. Tateishi, K., Ichiyama, T., Hirai, K. et al. Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study. Med Oncol 30, 450 (2013). https://doi.org/ 10.1007/s12032-012-0450-2
8. Y Inoue, N Inui, K Asada, M Karayama, et al. Phase II study of erlotinib in elderly patients with non- small cell lung cancer harboring epidermal growth factor receptor mutations. Cancer Chemotherapy and Pharmacology volume 76, pages155–161 (2015)
9. Phạm Văn Luận và cs. Kết quả điều trị Gefitinib bước một ở bệnh nhân cao tuổi mắc ung thư phổi không tế bào nhỏ giai đoạn tiến xa, có đột biến EGFR. Tạp chí y dược lâm sàng 108. 2021;16(6). https://doi.org/10.52389/tdls.v16i6.836
10. Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non –Small-Cell Lung Cancer. New England Journal of Medicine. 2002;346(2):92-98. doi:10.1056/NEJMoa011954.